Genetic Modification Therapies Clinical Applications: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing

Summary Table: Global Market for Genetic Modification Therapies, by Disease Category, Through 2023
Table 1: Scope of Report
Table 2: Genetic Modification Therapies Covered in Report
Table 3: Genetic Modification Platforms
Table 4: Key Market Growth Driving Forces of Genetic Modification Therapies
Table 5: Global Market for Genetic Modification Therapies, by Delivery Technology, Through 2023
Table 6: Genetic Modification Therapy Technology Life-Cycle Stage
Table 7: Characteristics of the Genetic Modification Therapies Industry
Table 8: Chemical Building Blocks of DNA and RNA
Table 9: DNA Translation and Transcription
Table 10: Long-range DNA Structure
Table 11: Genetic Variant Types
Table 12: Therapeutic Intervention Platforms
Table 13: Genetic Modification Approaches
Table 14: Distinct Features of the Genetic Modification Approaches
Table 15: Main Components of Gene Therapy Technology
Table 16: Gene Therapy Delivery Technology Parameters
Table 17: Clinical Criteria for Gene Therapy
Table 18: RNA Therapy Segments
Table 19: Gene Editing Therapeutic Interventions
Table 20: Gene Editing Technology Approaches
Table 21: Comparison of the Major Gene Editing Technologies
Table 22: Genetically Modified Cell Therapy Technologies
Table 23: Delivery Vector Technical Hurdles
Table 24: Comparison of Viral Vector Types
Table 25: Nonviral Delivery Methods
Table 26: Steps in Designing and Manufacturing a Gene Therapy Medicine
Table 27: Near-Term Applications for Genetic Modification Therapies
Table 28: Characteristics of Liver Organ
Table 29: Sectors within the Genetic Modification Therapies Industry
Table 30: Gene Editing Industry
Table 31: Gene Therapy Companies
Table 32: Genetically Modified Cell Therapy Clinical Industry
Table 33: RNA Therapy Companies
Table 34: GMP Clinical-Grade Lentiviral Manufacturing Companies
Table 35: Genetic Modification Therapies Industry Acquisitions, Jan. 2016-June 2018
Table 36: Genetic Modification Therapies Industry Strategic Alliances, Jan. 2016-June 2018
Table 37: Genetic Modification Therapies Key Market Growth Driving Forces
Table 38: Global Market for Genetic Modification Therapies, by Platform Technology, Through 2023
Table 39: Global Market for Gene Editing Therapies, by Disease Category, Through 2023
Table 40: Global Market for Gene Editing Therapies, by Technology, Through 2023
Table 41: Global Market for Gene Editing Therapies, by Delivery Type, Through 2023
Table 42: CRISPR Clinical Pipeline
Table 43: Global Market for Gene Therapy, by Disease Category, Through 2023
Table 44: Inherited Retinal Diseases
Table 45: Global Market for Gene Therapy, by Platform Technology, Through 2023
Table 46: Global Market for Gene Therapy, by Delivery Technology, Through 2023
Table 47: Gene Therapy AAV Vector Clinical Landscape
Table 48: Global Market for Genetically Modified Cell Therapy, by Disease Category, Through 2023
Table 49: Global Market for Genetically Modified Cell Therapy, by Platform Technology, Through 2023
Table 50: Global Genetically Modified Cell Therapy Market, by Delivery Technology, Through 2023
Table 51: Allogeneic versus Autologous Approaches
Table 52: Allogeneic Clinical and Preclinical Cell Therapy Programs
Table 53: Global Market for RNA Therapy, by Disease Category, Through 2023
Table 54: Global Market for RNA Therapy, by Platform Technology, Through 2023
Table 55: GalNAc-conjugated RNA Therapy Pipeline
Table 56: Global Market for RNA Therapy, by Delivery Technology, Through 2023
Table 57: Global Market for Genetic Modification Therapies, by Disease Category, Through 2023
Table 58: Indications Driving Market Growth
Table 59: Global Market for Genetic Modification Therapies Market, by Delivery Technology, Through 2023
Table 60: Global Market for Genetic Modification Medicines: Marketed and Late-Stage Pipeline
Table 61: Global Market for Genetic Modification Therapies in Cardiology, by Indication, Through 2023
Table 62: Global Market for Genetic Modification Therapies in Oncology, by Indication, Through 2023
Table 63: Barriers to CAR T-Cell Solid Tumor Development
Table 64: CAR T-Cell Solid Tumor Development Status
Table 65: Global Market for Genetic Modification Therapies in Ophthalmology, by Indication, Through 2023
Table 66: Global Market for Genetic Modification Therapies in Hematology, by Indication, Through 2023
Table 67: Hemophilia A and B: Drugs in Development
Table 68: Global Market for Genetic Modification Therapies in Musculoskeletal Applications, by Indication, Through 2023
Table 69: Global Market for Genetic Modification Therapies, by Indication, Through 2023
Table 70: Global Market for Genetic Modification Therapies in Rare Diseases, by Indication, Through 2023
Table 71: Global Market for Genetic Modification Therapies in Other Applications, by Indication, Through 2023
Table 72: Global Market for Genetic Modification Therapies, by Region, Through 2023
Table 73: Global Market for Gene Editing Therapy, by Region, Through 2023
Table 74: Global Market for Gene Therapy, by Region, Through 2023
Table 75: Global Market for Genetically Modified Cell Therapy, by Region, Through 2023
Table 76: Global Market for RNA Therapy, by Region, Through 2023
Table 77: CRISPR-Cas9 Patent Groups
Table 78: CRISPR-Cas9 Patent Licensing Fields
Table 79: Sangamo’s Collaboration Agreements Relating to ZFN Technology
Table 80: Sangamo Therapeutics’ Patent Position
Table 81: Oxford BioMedica’s Key Patents
Table 82: RNA Therapy Patents and Patent Applications, by Leading Companies
Table 83: CAR T-cell Patentable Technologies
Table 84: Affimers versus Antibodies for Gene Therapy Applications
Table 85: Gene Editing versus Gene Therapy Approach

Summary Figure: Global Market for Genetic Modification Therapies, by Disease Category, 2017-2023
Figure 1: Complexity of Therapeutic Approaches
Figure 2: Main Principle of Molecular Biology